Mixed microencapsulation of rat primary hepatocytes and Sertoli cells improves the metabolic function in a D-galactosamine and lipopolysaccharide-induced rat model of acute liver failure.
Hepatocyte transplantation is an alternative to transplantation of the whole liver. Compared with xenogeneic hepatocytes, primary hepatocytes have some advantages, such as a more powerful function and a smaller frequency of rejection caused by the host. Cell microencapsulation prevents direct access of host cells to the graft but cannot impede transfer of transplant-derived peptides, which can cross the physical barrier. Sertoli cells are central to the immune privilege demonstrated in the testis, and their actions have been utilized to protect cell transplants. Co-microencapsulating Sertoli cells with HepG2 cells has proved to be a valuable strategy in hepatocyte transplantation. Thus mixed microcapsules of primary rat hepatocytes and primary Sertoli cells may improve metabolic function in a d-galactosamine and lipopolysaccharide-induced rat model of acute liver failure.
Zheng
Ming-Hua
MH
Department of Infection and Liver Diseases, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.
Lin
Hai-Long
HL
Qiu
Li-Xin
LX
Cui
Yao-Li
YL
Sun
Qing-Feng
QF
Chen
Yong-Ping
YP
D000818:Animals; D002214:Capsules / Q000008:administration & dosage*; D018929:Cell Culture Techniques; D002460:Cell Line; D004195:Disease Models, Animal; D005688:Galactosamine / Q000633:toxicity; D022781:Hepatocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism*; D007108:Immune Tolerance; D008070:Lipopolysaccharides / Q000633:toxicity; D008099:Liver / Q000378:metabolism*; D017114:Liver Failure, Acute / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D008297:Male; D051381:Rats; D020127:Recovery of Function; D012708:Sertoli Cells / Q000166:cytology / Q000276:immunology / Q000378:metabolism*
D002214:Capsules; D008070:Lipopolysaccharides; D005688:Galactosamine